Functional outcomes for clinical trials in frail older persons: Time to be moving

William J. Evans, Shalender Bhasin, Elaine Cress, Mark A. Espeland, Luigi Ferrucci, Linda P. Fried, Thomas M. Gill, Marco Pahor, Stephanie Studenski, Jack Guralnik, Susan Nayfield, Sergei Romashkin, Basil A. Eldadah, Richard Suzman, John Haaga, Robert Perlstein, Laurie Burke, Mary Parks

Research output: Contribution to journalReview articlepeer-review


This is an exciting time with great potential for discovering therapies to improve functional capacity and decrease the high prevalence of frailty and disability in older people. The FDA will need to consider how best to incorporate the geriatric perspective into its mission. Cooperation between aging researchers, pharmaceutical companies, and regulators will be required to establish guidelines for outcome measures for the coming generation of clinical trials in frail older persons. Ultimately, all stakeholders have the same goals: reducing the burden of chronic disease and disability in older persons while avoiding harm.

Original languageEnglish (US)
Pages (from-to)160-164
Number of pages5
JournalJournals of Gerontology - Series A Biological Sciences and Medical Sciences
Issue number2
StatePublished - Feb 2008

ASJC Scopus subject areas

  • Aging
  • Geriatrics and Gerontology


Dive into the research topics of 'Functional outcomes for clinical trials in frail older persons: Time to be moving'. Together they form a unique fingerprint.

Cite this